Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 656 clinical trials
Clinical Database of Safe Personalized Adjuvant Breast Radiotherapy Based on Individual Radiosensitivity

Omission of radiotherapy has been suggested when luminal A tumor subtype is combined with clinical and pathologic factors defining a subgroup of patients with a low risk of ipsilateral breast recurrence.

cancer surgery
immunostimulant
breast irradiation
hypofractionated radiation therapy
cancer
  • 0 views
  • 19 Feb, 2024
Real-life Pan-HER-blockade With Neratinib

So far, there is no data available on treatment of patients with early-stage hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer, who completed adjuvant trastuzumab-based therapy less than one year ago, in the clinical routine setting. ELEANOR - designed as a prospective, longitudinal, non-interventional study …

breast neoplasm
epidermal growth factor
cancer
human epidermal growth factor
erbb2
  • 0 views
  • 19 Feb, 2024
Immediate Breast Reconstruction Following Mastectomy (IRMA)

Based on data from the US Surveillance, Epidemiology and End Result Program (SEER), the rates of nipple-sparing mastectomy (NSM) have risen 202% since 2009. In spite of the increasing popularity of IRMA, limited research has been done to identify complications in patients undergoing these procedures. Of particular importance is to …

mastectomy
breast reconstruction
  • 0 views
  • 19 Feb, 2024
Investigating National Solutions for Personalised Iodine-131 Radiation Exposure

This is a single-arm non-interventional prospective observational study to perform quantitative I-131 imaging and patient-specific dosimetry for patients undergoing radioiodine treatment.

thyroidectomy
radiation exposure
  • 0 views
  • 19 Feb, 2024
Cetuximab Therapeutic Drug Monitoring in Squamous Cell Carcinoma Head and Neck Cancer Patients: Determination of the Predictive Value Exposure Levels Through a Single Arm Multicentric Study

Only about 30 percent of cancer patients have a clinical benefit upon cetuximab administration. Pilot studies in colorectal and head and neck cancer patients have suggested that cetuximab pharmacokinetics (PK), i.e. clearance values, could impact on clinical outcomes such as survival.

fluorouracil
neck cancer
carboplatin
carcinoma
cancer
  • 0 views
  • 19 Feb, 2024
Which Type of Laparoscopic Colectomy Right or Left Have Better Postoperative Outcomes for the Patients?

Laparoscopic surgery decreased the morbidity of colorectal surgery. The two most common surgeries for colorectal cancer are right and left colectomy. Objective: To compare perioperative morbidity of the right versus left colectomy for cancer, as well as the quality of laparoscopic oncologic resection of both procedures.

  • 0 views
  • 19 Feb, 2024
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC

Immunotherapy for PD-L1 positive patients is still ineffective in some patientswhich may be related to the complex immune microenvironment.In view of this bottleneck, further refinement of immunotyping and in-depth study of drug resistance mechanism are the most important tasks. In this observational study, we evaluated the difference of gene mutation …

small cell lung cancer
  • 0 views
  • 19 Feb, 2024
Advanced Translational Research on Childhood Leukemia

Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of <50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity.

  • 0 views
  • 19 Feb, 2024
Autoantibodies Prevalence During Checkpoint Inhibitor Treatment

The use of Checkpoint inhibitors (ICIs) is rapidly expanding to the treatment of many cancer types. Autoimmunity and clinical autoimmune diseases represent adverse events of ICIs with variable severity and consequences. Clinical trials using ICIs have largely excluded patients with preexisting autoimmune diseases but the rate of autoimmune flares has …

  • 0 views
  • 19 Feb, 2024
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = >3 months).

  • 0 views
  • 19 Feb, 2024